Login / Signup

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Abhinav SharmaPedro MarquesBrendon L NeuenRobert A FletcherApril E HebertWally RapattoniFernando G AngClare ArnottAdeera LevinSubodh VermaVlado PerkovicKenneth W Mahaffey
Published in: Diabetes, obesity & metabolism (2023)
Keyphrases